Donepezil was no better than placebo for agitation in patients with Alzheimer disease

Van Reekum, Robert
March 2008
ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p7
Academic Journal
The article focuses on the randomized placebo-controlled trial investigating if Donepezil is better than placebo for clinically significant agitation that has not responded to psychosocial treatment in patients with Alzheimer disease. The trial, conducted with 259 patients (39 years of age), found out that Donepezil was no better than placebo for clinical agitation in patients with Alzheimer disease.


Related Articles

  • Alzheimer's Drug Approved.  // Medical Update;2003, Vol. 29 Issue 6, p7 

    Reports on the approval of Namenda, a class of drugs to treat moderate to severe cases of Alzheimer's disease, in the U.S. in December 2003. Results of clinical trials.

  • Treatment slows moderate to severe Alzheimer's disease. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);4/12/2003, Vol. 326 Issue 7393, p784 

    Reports that a treatment has been shown to slow the mental and physical decline of patients with moderate to severe Alzheimer's disease. How researchers in the United States conducted a double blind, randomized controlled trial of the drug memantine; Review of memantine by the U.S. Food and...

  • Cholinesterase Inhibition for Alzheimer Disease. Qizilbash, Nawab; Whitehead, Anne; Higgins, Julian; Wilcock, Gordon; Schneider, Lon; Farlow, Martin // JAMA: Journal of the American Medical Association;11/25/98, Vol. 280 Issue 20, p1777 

    Presents a study to determine the effects of cholinesterase inhibition with tacrine hydrochloride for the symptoms of Alzheimer disease in terms of cognitive performance, clinical global impression, behavior, and functional autonomy.

  • Promising trial results for Alzheimer's drug Reminyl.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p8 

    The article presents information on promising trial results for Alzheimer's drug, Reminyl. A recent clinical trial has found that the Alzheimer's disease treatment, Reminyl, may improve the ability of patients to perform day-today activities. The study of the Janssen Pharmaceutical Products LP...

  • An exercise and behavioral management program reduced functional dependence in Alzheimer disease: COMMENTARY. Stott, David J.; Taylor, Morven // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p77 

    Many clinicians question the effectiveness of rehabilitation for patients with Alzheimer disease. Emphasis is often placed on introducing coping strategies, rather than active rehabilitation with the aim of improving physical function, mood, and behavior. Few good clinical trials exist on which...

  • Trial disappointment for Forest Alzheimer's drug.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p9 

    The article presents information about trial disappointment for Forest laboratories Inc.'s drug for Alzheimer's disease. Forest Laboratories' investigational Alzheimer's disease treatment neramexane is no more effective than current therapies for the condition, according to a recent clinical...

  • chinese herb.  // Better Nutrition;Sep2008, Vol. 70 Issue 9, p14 

    The article presents information on a study which indicates that huperzine A, an alkaloid in Chinese club moss, may improve brain and behavioral functioning in some people suffering from Alzheimer's disease. The study examined 454 patients who were given either huperzine A or a placebo in...

  • Dementia capital. O'Neill, Graeme // Bulletin with Newsweek;2/5/2002, Vol. 120 Issue 6310, p28 

    Reports on a breakthrough research that may point to a better treatment for Alzheimer's disease in Australia. Impact of the build-up of copper levels and amyloid deposits in the neocortex region of the brain; Use of a metal-chelating agent to melt away ameloid deposits; Other research findings.

  • No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial. de Jong, Daniëlle; Jansen, René; Hoefnagels, Willibrord; Jellesma-Eggenkamp, Marja; Verbeek, Marcel; Borm, George; Kremer, Berry // PLoS ONE;2008, Vol. 3 Issue 1, p1 

    Background. The objective of this study was to determine whether treatment with the nonselective nonsteroidal anti-inflammatory drug (NSAID) indomethacin slows cognitive decline in patients with Alzheimer's disease (AD). Methodology/Principal Findings. This double-blind, randomized,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics